Comparison of biomarkers of COVID-19 patients with the alpha variant (B.1.1.7), the delta variant (B.1.617), and no mutation detected

Objectives: We aimed to compare biomarkers of COVID-19 patients with the Alpha variant (B.1.1.7), the Delta variant (B.1.617), and no mutation detected in our study. Methods: A total of 600 patients with positive COVID PCR test and Alpha, Delta variant and no mutation detected with Covid PCR mutation test were included in the study. Troponin I, creatinine, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Lactate Dehydrogenase (LDH), fibrinogen, D-dimer, ferritin, number of lymphocytes, lymphocytes (%), platelet (PLT), mean platelet volume (MPV), platelet distribution width (PDW), trombosite ratio in the blood (PCT), C-reactive protein (CRP) values were analyzed retrospectively. The age, gender, and hospitalization of the patients were evaluated concurrently. Results: Age, troponin, creatinine, LDH, PLT, MPV, and D-dimer were laboratory parameters that vary significantly with COVID-19 virus mutation. Age, troponin, LDH, and MPV values were lower in patients with Delta variant according to patients with the Alpha variant. Lymphocytes (N) and lymphocytes (%) values were lower in hospitalized patients relative to outpatients while age, troponin, LDH, CRP, and D-dimer values were higher in hospitalized patients than outpatients irrespective of mutation. Creatinine values were higher only in hospitalized patients with no mutation detected while ferritin and fibrinogen values were higher in hospitalized patients with Delta variant and no mutation detected. Conclusions: Age, troponin, creatinine, LDH, PLT, MPV, D-dimer, fibrinogen, ferritin, CRP, lymphocytes (N), and lymphocytes (%) values can guide to evaluate the diagnosis and hospitalization of patients with future different mutations.

Keywords:

COVID-19, alpha, delta, mutation biomarker,

PDF

___

1. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis 2022;22:35-42.
2. Gravagnuolo AM, Faqih L, Cronshaw C, Wynn J, Klapper P, Wigglesworth M. High throughput diagnostics and dynamic risk assessment of SARS-CoV-2 variants of concern. EBioMedicine 2021;70:103540.
3. Hemmer CJ, Löbermann M, Reisinger EC. COVID-19: epidemiology and mutations: an update. Radiologe 2021;61:880-7.
4. WHO. SARS- CoV-2 variants of concern and variants of interest. World Health Organization https://www.who. int/en/activities/tracking- SARS-CoV-2-variants/ 2021.
5. Thye AYK, Law JWF, Pusparajah P, Letchumanan V, Chan KG, Lee LH. Emerging SARS-CoV-2 variants of concern (VOCs): an impending global crisis. Biomedicines 2021;9:1303.
6. Volz, E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARS- CoV-2 lineage B.1.1.7 in England. Nature 2021;593:266-9.
7. Tao K, Tzou PL, Nouhin J, Gupta RK, Oliveira T, Kosakovsky Pond SL, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 2021;22:757-73.
8. Essa RA, Ahmed SK, Bapir DH, Rasul SA, Khdir AA, Abubakr CP. Clinical features and laboratory findings first case of B. 1.617.2 (delta) variant concern (VOC) in Iraq. Ann Med Surg (Lond) 2021;69:102814.
9. Bernal JL, Andrews N, Gower C, Public Health England Delta Variant Vaccine Effectiveness Study Group. Effectiveness of Covid-19 vaccines against the B.1.617. 2 (Delta) variant. N Engl J Med 2021;385:585-94.
10. Butt AA, Dargham SR, Chemaitelly H, Khal AA, Tang P, Hasan MR, et al. Severity of illness in persons infected with the SARS-CoV-2 delta variant vs beta variant in Qatar. JAMA Intern Med 2021;22;e217949.
11. Xia Y, Qi W, Li X, Yang Y, Cao J. Clinical efficacy and safety of QingshuYiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant: a protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e28184.
12. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.
13. Varmani SG, Chowhan RK, Sharma I, Narang R. COVID-19 and cardiovascular disease: Clinical implications of biochemical pathways. J Pract Cardiovasc Sci 2021;7:97-107.
14. Zaninotto M, Mion MM, Padoan A, Babuin L, Plebani M. Cardiac troponin I in SARS-CoV-2-patients: the additional prognostic value of serial monitoring. Clinica Chimica Acta 2022; 511:75-80.
15. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Napoli RD. Features, Evaluation, and Treatment of Coronavirus (COVID-19). Treasure Island (FL): StatPearls Publishing; 2022.
16. Henry BM, Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58:1021-8.
17. Violetis OA, Chasouraki AM, Giannou AM, Baraboutis IG. COVID-19 infection and haematological involvement: a review of epidemiology, pathophysiology and prognosis of full blood count findings. SN Compr Clin Med 2020;2:1089-93.
18. Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology 2021; 88:15-27.
19. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020;506:145-8.
20. Yıldırım Ö, Bayram M, Özmen RS, Soylu B, Dündar AS, Köksal AR. Evaluation of hematological indices in terms of COVID-19 related mortality and ICU admission. J Health Sci Med 2021;4:666-70.
21. Ozcelik N, Ozyurt S, Yilmaz Kara B, Gumus A, Sahin U. The value of the platelet count and platelet indices in differentiation of COVID-19 and influenza pneumonia. J Med Virol 2021;93:2221-6.
22. Ceyhan MA, Tümer M, Gürü S, Kadı S, Demir GG. Mean platelet volume and red cell distribution width values in patients with COVID-19 admitted to intensive care units or wards from emergency department. Arch Curr Med Res 2021;2:88-92.
23. Hassan S, Sheikh F N, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus 2020;12:e7355.
24. Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert Rev Hematol 2020;13:1265-75.
25. Di Micco P, Russo V, Carannante N, Imparato M, Cardillo G, Lodigiani C. Prognostic value of fibrinogen among COVID-19 patients admitted to an emergency department: an Italian cohort study. J Clin Med 2020;9:4134.
26. Cheng L, Li H, Li L, Liu C, Yan S, Chen H, et al. Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Lab Anal 2020;34:e23618.
27. Kunal S, Sharma SM, Sharma SK, Gautam D, Bhatia H, Mahla H, et al. Cardiovascular complications and its impact on outcomes in COVID-19. Indian Heart J 2020;72:593-8.
28. Birben B, Birben OD, Akın T, Akkurt G, Surel AA, Yakısık E, et al. Efficacy of the delta neutrophil index in predicting 30-day mortality in COVID-19 patients requiring intensive care. Int J Clin Pract 2021;75:e13970.
29. Frater JL, Zini G, d’Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. Int J Lab Hematol 2020;42:11-8.
30. Mao J, Dai R, Du RC, Zhu Y, Shui LP, Luo XH. Hematologic changes predict clinical outcome in recovered patients with COVID-19. Ann Hematol 2021;100: 675-89.
31. Wu J, Shi L, Zhang P, Wang Y, Yang H. Is creatinine an independent risk factor for predicting adverse outcomes in COVID-19 patients? Transpl Infect Dis 2021;23:e13539.
32. Alfano G, Ferrari A, Fontana F, Mori G, Ligabue G, Giovanella S, et.al. Twenty-four-hour serum creatinine variation is associated with poor outcome in the novel coronavirus disease 2019 (COVID-19) patients. Kidney Res Clin Pract 2021;40:231-40.
33. Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalizations: systematic review and meta-analysis. BMJ Evid Based Med 2021;26:107-8.
34. Zhang Y, Zheng L, Liu L, Zhao M, Xiao J. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China. Liver Int 2020;40:2095-103.
35. Li C, Ye J, Chen Q, Hu W, Wang L, Fan Y, et al. Elevated lactate dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19. Aging (Albany NY) 2020;12:15670-81.
36. Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med 2020;38:1722-6.
37. Acer Ö, Bahce YG, Özüdoğru O. Association of viral load with age, gender, disease severity, and death in severe acute respiratory syndrome coronavirus 2 variants. J Med Virol 2022;94:3063-9.
38. Chun JY, Jeong H, Kim Y. Age-varying susceptibility to the delta variant (B.1.617.2) of SARS-CoV-2. JAMA Network Open 2022;5:e223064.
39. Cetin M, Balcı PO, Sivgin H, Cetin S, Ulgen A, Demir HD, et al. Alpha variant (B.1.1.7) of SARS-CoV-2 increases fatality-rate for patients under age of 70 years and hospitalization risk overall. Acta Microbiol Immunol Hung 2021;3:153-61.
40. Özüdoğru O, Acer O, Bahçe YG. Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics. J Med Virol 2022;94:3706-13.
41. Anadolu agency.'Turkiye, Health', 20.08.2021. https://www.aa.com.tr/en/health/over-90-of-covid-cases-in-turkey-are-delta-variant-health-minister/2341624.
42. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:759-65.
43. Veneti L, Salamanca BV, Seppälä E, Starrfelt J, Storm ML, Bragstad K, et al. No difference in risk of hospitalization between reported cases of the SARS-CoV-2 delta variant and alpha variant in Norway. Int J Infect Dis 2022;115:178-84.
44. Ryu BH, Hong SI, Lim SJ, Cho Y, Hwang C, Kang H, et al. Clinical features of adult COVID-19 patients without risk factors before and after the nationwide SARS-CoV-2 B.1.617.2 (Delta)-variant outbreak in Korea: experience from Gyeongsangnam-do. J Korean Med Sci 2021;36:e341.
45. Odabasi MS, Ozkaya G, Serin E, Akkus A, Yilmaz P, Sayan I. Laboratory findings in predicting intensive care need and death of COVID-19 patients. Int J Med Biochem 2021;4:77-84.
46. Barrett TJ, Bilaloglu S, Cornwell M, Burgess HM, Virginio VW, Drenkova K, et al. Platelets contribute to disease severity in COVID-19. J Thromb Haemost 2021;19:3139-53.